Banner Life Sciences Announces Final FDA Approval of BAFIERTAM for Multiple Sclerosis

BAFIERTAM™ (monomethyl fumarate), the bioequivalent alternative to Biogen’s Tecfidera® (dimethyl fumarate), is a new oral treatment option for relapsing forms of multiple sclerosis